Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide.
Horowitz
M
M
Vilsbøll
T
T
Zdravkovic
M
M
Hammer
M
M
Madsbad
S
S
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced*; D052216:Glucagon-Like Peptide 1 / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D054795:Incretins / Q000009:adverse effects*; D000069450:Liraglutide; D008297:Male; D008875:Middle Aged
D054795:Incretins; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1